Effect of Glucagon-like Peptide-1 Receptor Agonist on Cardiac Structure and Function in Patients with Heart Failure: A Systematic Review and Meta-analysis

Xinyu Zhang; Hongyuan Zhang

doi:10.53941/ijddp.2023.100010

Abstract

Recent clinical trials have shown that glucagon-like peptide-1 receptor agonists (GLP-1RAs) yield positive effects on composite cardiovascular endpoints, rendering them potentially promising therapeutic agents for heart failure (HF). This study analysed the effect of GLP-1RAs on cardiac structure and function in HF patients. MethodsA comprehensive search was conducted across PubMed, Cochrane Library, Ovid Embase, Ovid Medline, and Web of Science databases, spanning from inception to August 1, 2022, to identify randomised controlled trials (RCTs) comparing alterations in cardiac structure and function in HF patients receiving GLP-1RAs or placebo. Cardiac structures were assessed through left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), and left ventricular mass (LVM). Systolic function was evaluated using left ventricular ejection fraction (LVEF), stroke volume (SV), and global longitudinal strain (GLS). Diastolic function was assessed via the early to late diastolic filling velocity ratio (E/A ratio) and the early transmitral filling velocity to early diastolic mitral annular velocity ratio (E/e ratio). The I2 statistic was used to test heterogeneity. Pooled relative risks were calculated using random-effects models. Potential publication bias was assessed using the Cochrane Risk of Bias 2 tool. ResultsA total of 1,417 patients from 16 randomised placebo-controlled trials were enrolled in this meta-analysis. Among all HF patients, GLP-1RAs demonstrated improvement in diastolic function as indicated by E/A (MD = -0.15; 95% CI: -0.21 to -0.09; P < 0.00001; I2 = 43%) and E/e’ (MD = -0.82; 95% CI: -1.53 to -0.11; P = 0.02; I2= 62%). However, GLP-1RAs did not exhibit any improvement in cardiac structure and systolic function parameters for HF patients. ConclusionGLP-1RAs demonstrated potential for improving diastolic function in HF patients, but did not show any impact on systolic function and cardiac structure. Therefore, the application of GLP-1RAs should be based on the specific HF type and accompanying comorbidities.

References

1.
Roth, G.A. ； Mensah, G.A. ； Johnson, C . O . et al. Global Burden of Cardiovascular Diseases and Risk Factors , 1990 -2019: Update From the GBD 2019 Study. J. Am. Coll. Cardiol., 2020 . 76 ( 25 ): p. 2982 - 3021 .
2.
Rodgers, J.L. ； Jones, J. ； Bolleddu, S. I. ; et al.,Cardiovascular Risks Associated with Gender and Aging . J. Cardiovasc. Dev. Dis. , 2019 , 6 ( 2 ).
3.
Dunlay, S.M. ; Givertz, M.M. ; Aguilar, D. ; et al . Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update . Circulation , 2019 , 140 ( 7 ): e294 - e324 .
4.
Dei Cas, A. ; Fonarow, G.C. ; Gheorghiade, M. ; et al . Concomitant diabetes mellitus and heart failure . Curr. Probl. Cardiol. , 2015 , 40 ( 1 ): 7 - 43 .
5.
Boonman-de Winter, L.J. ; Rutten, F.H. ; Cramer, M.J. ; et al . High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes . Diabetologia ， 2012 , 55 ( 8 ): 2154 - 2162 .
6.
From, A.M. ; Leibson, C.L. ; Bursi, F. ; et al . Diabetes in heart failure: prevalence and impact on outcome in the population . Am. J. Med. , 2006 , 119 ( 7 ): 591 - 599 .
7.
Nichols, G.A. ; Gullion, C.M. ; Koro, C.E. ; et al . The incidence of congestive heart failure in type 2 diabetes: an update . Diabetes Care , 2004 , 27 ( 8 ): 1879 - 1884 .
8.
McMurray, J.J. ; Packer, M. ; Desai, A.S. ; et al . Angiotensin-neprilysin inhibition versus enalapril in heart failure . N. Engl. J. Med. , 2014 , 371 ( 11 ): 993 - 1004 .
9.
Ponikowski, P. ； Voors, A.A. ; Anker, S.D. ; et al . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) . Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. , 2016 , 18 ( 8 ): 891 - 975 .
10.
Yancy, C.W. ; Jessup, M. ; Bozkurt, B. ; et al . 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America . J. Am. Coll. Cardiol. , 2017 , 70 ( 6 ): 776 - 803 .
11.
Packer, M. ; Anker, S.D. ; Butler, J. ; et al . Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure . N. Engl. J. Med. , 2020 , 383 ( 15 ): 1413 - 1424 .
12.
McMurray, J . J .V.; Solomon S.D. ; Inzucchi S.E.; et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N. Engl. J. Med., 2019 , 381 ( 21 ): 1995 - 2008 .
13.
Zannad, F. ; Ferreira, J.P. ; Pocock, S.J. ; et al . SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials . Lancet , 2020 , 396 ( 10254 ): 819 - 829 .
14.
Armstrong, P.W. ; Pieske, B. ; Anstrom, K.J. ; et al . Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction . N. Engl. J. Med. , 2020 , 382 ( 20 ): 1883 - 1893 .
15.
Teerlink, J.R. ; Diaz, R. ; Felker, G.M. ; et al . Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure . N. Engl. J. Med. , 2021 , 384 ( 2 ): 105 - 116 .
16.
Marx, N. ; Husain, M. ; Lehrke, M. ; et al . GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes . Circulation , 2022 , 146 ( 24 ): 1882 - 1894 .
17.
Cosentino, F. ; Grant, P.J. ; Aboyans, V. ; et al . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD . Eur. Heart J. , 2020 , 41 ( 2 ): 255 - 323 .
18.
Giugliano, D. ; Scappaticcio, L. ; Longo, M. ; et al . GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs . Cardiovasc. Diabetol. , 2021 , 20 ( 1 ): 189 .
19.
Palmer, S.C. ; Tendal, B. ; Mustafa, R.A. ; et al . Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials . B.M.J. , 2021 , 372 : m4573 .
20.
Natali, A. ; Nesti, L. ; Tricò, D. ; et al . Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence . Cardiovasc. Diabetol. , 2021 , 20 ( 1 ): 196 .
21.
Wong, S.Y. ; Lee, A . R .Y.B.; Sia A . H .J.; et al. Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials. Cardiovasc. Drugs Ther., 2022 .
22.
Page, M.J. ； McKenzie, J.E. ; Bossuyt, P.M. ; et al . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews . B.M.J. , 2021 , 372 : n71 .
23.
Bizino, M.B. ; Jazet, I.M. ; Westenberg, J . J .M.; et al. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol . 2019 Apr 30 ; 18 ( 1 ): 55 . doi: 10.1186/s12933-019-0857-6. Erratum in: Cardiovasc. Diabetol. , 2019 , 18 ( 1 ): 101 .
24.
Bojer, A.S. ; Sørensen, M.H. ; Bjerre, J. ; et al . Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial . Diabetes Obes. Metab. , 2021 , 23 ( 10 ): 2374 - 2384 .
25.
Jorsal, A. ; Kistorp, C. ; Holmager, P. ; et al.Effect of liraglutide, glucagon-like peptide-1 analogue, a ,on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre,double-blind,randomised, trial, placebo-controlled . Eur . J. Heart Fail. , 2017 , 19 ( 1 ): 69 - 77 .
26.
Lepore, J.J. ; Olson, E. ; Demopoulos, L. ; et al . Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction . J.A.C.C. Heart Fail. , 2016 , 4 ( 7 ): 559 - 566 .
27.
Margulies, K.B. ; Hernandez, A.F. ; Redfield, M.M. ; et al . Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial . J.A.M.A. , 2016 , 316 ( 5 ): 500 - 508 .
28.
Nielsen, R. ; Jorsal, A. ; Iversen, P. ; et al . Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study . J. Nucl. Cardiol. , 2019 , 26 ( 2 ): 585 - 597 .
29.
Wägner, A.M. ; Miranda-Calderín, G. ; Ugarte-Lopetegui, M . A,; et al. Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2). Diabetes. Metab. , 2019 , 45 ( 3 ): 268 - 275 .
30.
Zhang, J.Y. ; Wang, X.Y. ; Wang, X . Effects of liraglutide on hemodynamic parameters in patients with heart failure . Oncotarget , 2017 , 8 ( 37 ): 62693 - 62702 .
31.
Nielsen, R. ; Jorsal, A. ; Tougaard, R.S. ; et al . The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes . Diabetes Obes. Metab. , 2020 , 22 ( 11 ): 2141 - 2150 .
32.
Kumarathurai, P. ; Anholm, C. ; Nielsen, O.W. ; et al . Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study . Cardiovasc. Diabetol. , 2016 , 15 ( 1 ): 105 .
33.
Kumarathurai, P. ; Sajadieh, A. ; Anholm, C. ; et al . Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study . Cardiovasc. Diabetol. , 2021 , 20 ( 1 ): 12 .
34.
Chen, W.R. ; Shen, X.Q. ; Zhang, Y. ; et al . Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction . Endocrine , 2016 , 52 ( 3 ): 516 - 526 .
35.
Roos, S.T. ; Timmers, L. ; Biesbroek, P.S. ; et al . No benefit of additional treatment with exenatide in patients with an acute myocardial infarction . Int. J. Cardiol. , 2016 , 220 : 809 - 8114 .
36.
Woo, J.S. ; Kim, W. ; Ha, S.J. ; et al . Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study . Arterioscler. Thromb. Vasc. Biol. , 2013 , 33 ( 9 ): 2252 - 2260 .
37.
Paiman, E . H .M.; van Eyk H.J. ; van Aalst M. M .A.; et al. Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double-Blind, Randomized, Placebo-Controlled Trial. J. Magn. Reson. Imaging, 2020 , 51 ( 6 ): 1679 - 1688 .
38.
Scalzo, R.L. ; Moreau, K.L. ; Ozemek, C. ; et al . Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes . J. Diabetes Complications , 2017 , 31 ( 2 ): 449 - 455 .
39.
Rowlands, J. ; Heng, J. ; Newsholme, P. ; et al . Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function . Front. Endocrinol (Lausanne). , 2018 , 9 : 672 .
40.
Drucker, D . J . The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab. , 2016 , 24 ( 1 ): 15 - 30 .
41.
Baggio, L.L. ; Yusta, B. ; Mulvihill, E.E. ; et al . GLP-1 Receptor Expression Within the Human Heart . Endocrinology , 2018 , 159 ( 4 ): 1570 - 1584 .
42.
Robinson, E. ; Cassidy, R.S. ; Tate, M. ; et al . Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix . Basic Res. Cardiol. , 2015 , 110 ( 2 ): 20 .
43.
Chen, J. ; Xu, S. ; Zhou, W. ; et al . Exendin-4 Reduces Ventricular Arrhythmia Activity and Calcium Sparks-Mediated Sarcoplasmic Reticulum Ca Leak in Rats with Heart Failure . Int. Heart J. , 2020 , 61 ( 1 ): 145 - 152 .
44.
Munaf, M. ; Pellicori, P. ; Allgar, V. ; et al . A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure . Int. J. Pept. , 2012 , 2012 : 249827 .
45.
McKee, A. ; Al-Khazaali, A. ; Albert, S . G . Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM. J. Endocr. Soc. , 2020 , 4 ( 5 ): bvaa037 .

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us